



CLYMB
CLINICAL

Integrating TFL Designer with CDISC 360: Advancing Automation and Concept-Based Standards in Clinical Trial Analysis & Reporting

Bhavin Busa

Oct 18, 2023


Session 4C: COSA Session - 360 & End-to-End

2023
US
INTERCHANGE

FALLS CHURCH, VA | 18-19 OCTOBER




WS1



Create concepts in knowledge graphs

WS2

Transform concepts in machine readable form




WS3



Add transformation semantics


Use Case 1: Selecting standards concepts and linked metadata needed for a study
 Use Case 2: Adding study design, concept configuration & generate artifacts
 Use case 3: Automatic population of data into artifacts

WS4




Identify and select standards specification (Use Case 1)

WS5



Configure study specification and create artifacts (Use Case 2)


WS6



Automatically process and transform data (Use Case 3)

Use Case 3 : Execute


Automatic population of data into artifacts



Data Collection Scope

Use Case 3 : Execute


Automatic population of data into artifacts



CDISC 360 PoC

WS4 & 6

WS6



CDISC 360: The Art of the Possible

Powered by Microsoft

Search the CDISC Library

Selection Summary

- Disease Area
✓ Endocrine
- Therapeutic Area
✓ Diabetes - Type 2
- Standards Focus
✓ Study Endpoint
- Study Endpoint
✓ Analysis of Glycated Hemoglobin
- Standard Analyses
✓ Mean Change from Baseline in HbA1c (%) Over Time
- Selection Summary**
Endocrine
Diabetes - Type 2
Study Endpoint
Analysis of Glycated Hemoglobin
Mean Change from Baseline in HbA1c (%) Over Time

Study Endpoint

Analysis of Glycated Hemoglobin

Analysis of the continuous clinical endpoint of HbA1c. Example: a Phase III, parallel-group study designed to determine efficacy of Drug A for patients with Type II diabetes. The primary endpoint defined as the change in HbA1c from baseline.

[View details](#)

Analysis

Mean Change from Baseline in HbA1c (%) Over Time

Time (Weeks)	Drug A (Mean Change %)	Drug B (Mean Change %)
0	0.0	0.0
4	-1.5	1.5
8	-3.0	3.0
12	-4.5	4.5
14	-5.5	5.5

Provides a visual display of the information in the "HbA1C Longitudinal Repeated Measures Analysis" table. Includes additional weeks beyond those in that table. The mean changes shown are based on adjusted changes from baseline from the repeated measures model.

[View details](#)
[View analysis results metadata](#)

Analysis Datasets

ADSL

Analysis Data Subject Level

[View analysis dataset metadata](#)
[View sample analysis data](#)
[View analysis dataset structure](#)

ADHBA1C

DBS - Structured Dataset

[View analysis dataset metadata](#)
[View sample analysis data](#)
[View analysis dataset structure](#)

[Back](#) [Save Selection](#)

Current State: Analysis Results Deliverables

Manual process in designing TFL shells/layout and ADaM specifications


Programmer writes the SAS code to generate analysis deliverables (sometime with macros or re-using the code)

Too much variability across studies, disease areas, and organization

Static results with no or limited linking facility (e.g., to Protocol, SAP, ADaM data)

There is no industry standard for analysis results

Poll Summary*



* Results from the live poll (n=253 responders) conducted during the TFL Designer Virtual Design Thinking Workshop (Part I), 13th Sep 2022, Bhavin Busa

Who attended the workshop:

- Clinical / Statistical Programmer (**63%**)
- Biostatisticians (**14%**)
- Data Standards Expert (**13%**)
- Other (**12%**)

Top 5 pain points:

1. Too much variability across studies / disease areas / organizations
2. No industry-wide standards exist
3. TFL metadata and shells are not machine-readable
4. Multiple manual steps in the process
5. Limited or no automation exist

Programming is more of a Science (**50%**) than it is an Art (**39%**)!



74% organizations have TFL standards or templates

Who generates TFL shells (mock-ups)?
57% - Biostatistician
31% - Biostats & Programmers

87% responders confirmed their TFL shells are NOT machine-readable

65% responders uses MS Word / RTF for TFL shells generation

40% annotate their TFL mock-up shells to provide results metadata information

76% do not generate analysis results metadata prospectively to use in their TFL program


82% confirmed not having machine-readable TFL analysis results metadata

Out of the responders who use machine-readable ARM: MS Excel (**14%**) and SAS (**10%**) are top 2 format choices

CDISC Analysis Results Standard – Coming Soon!



All You Need to Know about the New CDISC Analysis Result Standards!



PharmaSUG 2023: Paper # MM327

Bhavin Busa, Richard Marshall, Bess LeRoy

Analysis Results Standard Public Repo on GitHub

- <https://github.com/cdisc-org/analysis-results-standard>

The screenshot shows the GitHub repository page for 'cdisc-org / analysis-results-standard'. The repository is public and has 11 stars and 1 fork. The main content area shows a file tree with folders like 'HowTos', 'documents', 'images', 'model', 'project', 'workfiles', and files like 'CODE_OF_CONDUCT.md', 'CONTRIBUTING.md', 'LICENSE', and 'README.md'. The 'README.md' file is open, showing the project's goals and a list of tasks. Callout boxes highlight specific features: 'Model: representations of the model (YAML, JSON, Mermaid ER, YUML, SVG)', 'Workfiles: CMAP, examples', 'Project: Auto-generated content (Python classes/API, documentation, model structures)', and 'To come: Utilities, API Dev'.

File/Folder	Description	Commit Date
HowTos	Initial commit	4 months ago
documents	Delete ICH guideline	last month
images	Add files via upload	yesterday
model	Generated project and ER diagram	5 days ago
project	Generated project and ER diagram	5 days ago
workfiles	Generated project and ER diagram	5 days ago
CODE_OF_CONDUCT.md	Update CODE_OF_CONDUCT.md	3 weeks ago
CONTRIBUTING.md	Update CONTRIBUTING.md	3 weeks ago
LICENSE	Initial commit	4 months ago
README.md	Merge branch 'main' into admin-docs-patch-1	35 minutes ago


Model: representations of the model (YAML, JSON, Mermaid ER, YUML, SVG)

Workfiles: CMAP, examples


Project: Auto-generated content (Python classes/API, documentation, model structures)


To come: Utilities, API Dev

ARS Model Representation using CMAP*




Future State: Analysis Results Deliverables





Streamlining Analysis Data Flow



cdisc

Site Number:

Subject Number:

Form AE - Adverse Events

1 AE - Adverse Events

1.1 Were any adverse events experienced? No Yes **AEYN**

1.2 What is the adverse event term? **AETERM**

1.3 Start Date (DD-MMM-YYYY) **AESTDAT**

1.4 Ongoing No Yes **AEONGO**

1.5 End Date (DD-MMM-YYYY) **AEENDAT**

1.6 Severity Mild Moderate Severe **AESEV**

Adverse Events

Table 35. Patients With Adverse Events¹ by System Organ Class, Safety Population, Pooled Analysis (or Trial X)²

System Organ Class	Drug Name Dosage X N = XXX n (%)	Drug Name Dosage Y N = XXX n (%)	Active Control N = XXX n (%)	Placebo N = XXX n (%)	Risk Difference (%) (95% CI) ^{3,4}
Blood and lymphatic system	n (%)	n (%)	n (%)	n (%)	X (Y, Z)
Cardiac disorders	n (%)	n (%)	n (%)	n (%)	X (Y, Z)
Ear and labyrinth disorders	n (%)	n (%)	n (%)	n (%)	X (Y, Z)
Endocrine disorders	n (%)	n (%)	n (%)	n (%)	X (Y, Z)
Eye disorders	n (%)	n (%)	n (%)	n (%)	X (Y, Z)
Gastrointestinal disorders	n (%)	n (%)	n (%)	n (%)	X (Y, Z)
Hepatobiliary disorders	n (%)	n (%)	n (%)	n (%)	X (Y, Z)
Immune system disorders	n (%)	n (%)	n (%)	n (%)	X (Y, Z)
Infections and infestations	n (%)	n (%)	n (%)	n (%)	X (Y, Z)
Injury, poisoning and procedural complications	n (%)	n (%)	n (%)	n (%)	X (Y, Z)

Source: [include Applicant source, datasets and/or software tools used].

¹ Treatment-emergent adverse event defined as [definition].

² Duration = [e.g., X week double-blind treatment period or median and a range indicating pooled trial durations].

³ Difference is shown between [treatment arms] (e.g., difference is shown between Drug Name dosage X vs. placebo).

⁴ Table display is ordered by the risk difference.

Abbreviations: CI, confidence interval; N, number of patients in treatment arm; n, number of patients with at least one event

Keeping End in Mind




TFL Designer – Key Highlights

- Software as a Service (SaaS) Solution
- Digitizes your analysis results (TFL)
- Aligned with CDISC Analysis Results Standards
- Central repository for your TFL standards, display templates, conventions and metadata
- Automates generation of TFL shells and provides machine-readable metadata
- Community & Enterprise versions

Key Functionalities

- *Central repository for your TFL standards/templates, conventions and metadata*
- *Access to library of TFL templates (community and user generated) by disease areas, TA, and indication*
- *Access to CDISC Standards (SDTM, ADaM, CT) via API to CDISC Library*
- *Develop new mock-up shells, edit/delete items*
- *Automatically populate items based on user inputs*
- *Export TFL shells in RTF & PDF formats*
- *Export and import analysis results metadata in various machine-readable formats*

Visit Clymb or COSA Booth for TFL Designer (Community) Demo



Thursday, 19th Oct (Day 2)

@COSA Booth

10:30	11:00
11:00	11:30
11:30	12:00
12:00	12:30

@Clymb Booth

14:00	14:30
14:30	15:00
15:00	15:30
15:30	16:00




What are we trying to accomplish?

- Build an industry leading software solution that automates TFL design and generation process [community & enterprise versions]
- Partner with companies to improve their internal TFL standards and processes
- Quantify process improvements and continue to build future state automation (target 40-50% efficiency)
- Accelerate study timelines to allow your team to get data quicker
- CDISC 360 Vision: From PoC to Reality

Challenging the Status Quo

Hackles

By Drake Emko & Jen Brodzik




<http://hackles.org>

Copyright © 2001 Drake Emko & Jen Brodzik

"copy-paste programming" to "meta-programming"

TFL / Analysis Results – Clymb Vision



 = Automated Process



Bhavin Busa, Principal & Co-founder
bhavin@clymbclinical.com
631-220-5446



EMAIL
info@clymbclinical.com



WEBSITE
www.clymbclinical.com



PHONE
781-692-3613

References

1. [All You Need to Know about the New CDISC Analysis Result Standards!](#), PharmaSUG 2023: Paper # MM327, Bhavin Busa, Richard Marshall, Bess LeRoy
2. CDISC Analysis Results Standard GitHub, 2023: <https://github.com/cdisc-org/analysis-results-standard>
3. [CDISC 360 White Paper](#)
4. CDISC 360 - The Journey so Far and the Road Ahead, Peter Van Reusel, 28th April 2020